Cite

HARVARD Citation

    Buonerba, C. et al. (2013). Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. Future oncology. pp. 889-897. [Online]. 
  
Back to record